Literature DB >> 22338051

Clinical and pathologic features of secondary acute promyelocytic leukemia.

Amy S Duffield1, Joseph Aoki, Mark Levis, Kathleen Cowan, Christopher D Gocke, Kathleen H Burns, Michael J Borowitz, Milena Vuica-Ross.   

Abstract

Acute promyelocytic leukemia (APL) is a relatively common form of acute myeloid leukemia (AML) that has an excellent prognosis. In contrast, secondary acute myeloid leukemias, including therapy-related AML and AML with myelodysplasia-related changes, have a relatively poor prognosis. We identified 9 cases of APL at our institution in which there was a history of chemotherapy, radiotherapy, chronic immunosuppression, or antecedent myelodysplastic syndrome. The clinical and pathologic findings in these cases of secondary APL were compared with the clinical and pathologic findings in cases of de novo APL. We found that secondary and de novo APL had abnormal promyelocytes with similar morphologic and immunophenotypic features, comparable cytogenetic findings, comparable rates of FMS-like tyrosine kinase mutations, and similar rates of recurrent disease and death. These data suggest that secondary APL is similar to de novo APL and, thus, should be considered distinct from other secondary acute myeloid neoplasms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22338051      PMCID: PMC3578661          DOI: 10.1309/AJCPE0MV0YTWLUUE

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  27 in total

1.  Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis.

Authors:  Emanuele Ammatuna; Pau Montesinos; Syed Khizer Hasan; Safaa M Ramadan; Jordi Esteve; Maximillian Hubmann; Maria Pagoni; David Grimwade; Miguel Angel Sanz; Francesco Lo-Coco
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

2.  CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.

Authors:  F Ferrara; F Morabito; B Martino; G Specchia; V Liso; F Nobile; P Boccuni; R Di Noto; F Pane; M Annunziata; E M Schiavone; M De Simone; C Guglielmi; L Del Vecchio; F Lo Coco
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

3.  Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.

Authors:  N Mauritzson; M Albin; L Rylander; R Billström; T Ahlgren; Z Mikoczy; J Björk; U Strömberg; P G Nilsson; F Mitelman; L Hagmar; B Johansson
Journal:  Leukemia       Date:  2002-12       Impact factor: 11.528

4.  Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop.

Authors:  Mette K Andersen; Richard A Larson; Nils Mauritzson; Susanne Schnittger; Suresh C Jhanwar; Jens Pedersen-Bjergaard
Journal:  Genes Chromosomes Cancer       Date:  2002-04       Impact factor: 5.006

5.  Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop.

Authors:  Harold J Olney; Felix Mitelman; Bertil Johansson; Krzysztof Mrózek; Roland Berger; Janet D Rowley
Journal:  Genes Chromosomes Cancer       Date:  2002-04       Impact factor: 5.006

6.  Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.

Authors:  S De Botton ; S Chevret; M Sanz; H Dombret; X Thomas; A Guerci; M Fey; C Rayon; F Huguet; J J Sotto; C Gardin; P Cony Makhoul ; P Travade; E Solary; N Fegueux; D Bordessoule; J San Miguel ; H Link; B Desablens; A Stamatoullas; E Deconinck; K Geiser; U Hess; F Maloisel; S Castaigne; C Preudhomme; C Chomienne; L Degos; P Fenaux
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

7.  Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.

Authors:  Lee-Yung Shih; Ming-Chung Kuo; Der-Cherng Liang; Chein-Fuang Huang; Tung-Liang Lin; Jin-Hou Wu; Po-Nan Wang; Po Dunn; Chang-Liang Lai
Journal:  Cancer       Date:  2003-09-15       Impact factor: 6.860

8.  Therapy-related acute promyelocytic leukemia.

Authors:  M Beaumont; M Sanz; P M Carli; F Maloisel; X Thomas; L Detourmignies; A Guerci; N Gratecos; C Rayon; J San Miguel; J Odriozola; J Y Cahn; F Huguet; A Vekhof; A Stamatoulas; H Dombret; F Capote; J Esteve; A M Stoppa; P Fenaux
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

9.  Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML.

Authors:  A Kakizuka; W H Miller; K Umesono; R P Warrell; S R Frankel; V V Murty; E Dmitrovsky; R M Evans
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

10.  Therapy-related acute promyelocytic leukemia: a report on 16 cases.

Authors:  L Detourmignies; S Castaigne; A M Stoppa; J L Harousseau; A Sadoun; M Janvier; J L Demory; M Sanz; R Berger; F Bauters
Journal:  J Clin Oncol       Date:  1992-09       Impact factor: 44.544

View more
  10 in total

1.  CD34(+) therapy-related acute promyelocytic leukemia in a patient previously treated for breast cancer.

Authors:  John Savooji; Fouzia Shakil; Humayun Islam; Delong Liu; Karen Seiter
Journal:  Stem Cell Investig       Date:  2016-03-11

Review 2.  Global characteristics of childhood acute promyelocytic leukemia.

Authors:  L Zhang; A Samad; M S Pombo-de-Oliveira; G Scelo; M T Smith; J Feusner; J L Wiemels; C Metayer
Journal:  Blood Rev       Date:  2014-09-30       Impact factor: 8.250

3.  Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Authors:  S Kayser; J Krzykalla; M A Elliott; K Norsworthy; P Gonzales; R K Hills; M R Baer; Z Ráčil; J Mayer; J Novak; P Žák; T Szotkowski; D Grimwade; N H Russell; R B Walter; E H Estey; J Westermann; M Görner; A Benner; A Krämer; B D Smith; A K Burnett; C Thiede; C Röllig; A D Ho; G Ehninger; R F Schlenk; M S Tallman; M J Levis; U Platzbecker
Journal:  Leukemia       Date:  2017-03-21       Impact factor: 11.528

4.  Acute promyelocytic leukemia after renal transplant and filgrastim treatment for neutropenia.

Authors:  Jaime A Campbell; John R Krause
Journal:  Proc (Bayl Univ Med Cent)       Date:  2016-10

Review 5.  Therapy-related acute promyelocytic leukemia: a systematic review.

Authors:  Armin Rashidi; Stephen I Fisher
Journal:  Med Oncol       Date:  2013-06-15       Impact factor: 3.064

6.  Chromosomal abnormality of acute promyelocytic leukemia other than PML-RARA: a case report of acute promyelocytic leukemia with del(5q).

Authors:  Osamu Imataki; Makiko Uemura
Journal:  BMC Clin Pathol       Date:  2016-10-04

7.  Evaluation of prognostic factors in patients with therapy-related acute myeloid leukemia.

Authors:  Sang Hyuk Park; Hyun-Sook Chi; Young-Uk Cho; Seongsoo Jang; Chan-Jeoung Park
Journal:  Blood Res       Date:  2013-09-25

Review 8.  Therapy-related myeloid neoplasms: clinical perspectives.

Authors:  Luana Fianchi; Marianna Criscuolo; Emiliano Fabiani; Giulia Falconi; Alessio Maria Edoardo Maraglino; Maria Teresa Voso; Livio Pagano
Journal:  Onco Targets Ther       Date:  2018-09-17       Impact factor: 4.147

9.  Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases.

Authors:  Yenny Alejandra Moreno Vanegas; Abdel-Ghani M Azzouqa; David M Menke; James M Foran; Prakash Vishnu
Journal:  Hematol Rep       Date:  2018-09-05

10.  Therapy-related acute promyelocytic leukemia with FMS-like tyrosine kinase 3-internal tandem duplication mutation in solitary bone plasmacytoma: A case report.

Authors:  Li-Li Hong; Xian-Fu Sheng; Hai-Feng Zhuang
Journal:  World J Clin Cases       Date:  2020-10-06       Impact factor: 1.337

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.